Hepatic arterial infusion chemotherapy (HAIC) has often been used as a therapeutic option for patients with advanced hepatocellular carcinoma (HCC). This study aimed to evaluate the efficacy and safety of HAIC using cisplatin with or without 5-fluorouracil in patients with advanced HCC.
Between January 2002 and December 2007, we enrolled patients with advanced HCC who underwent HAIC via implantable port systems with cisplatin (60 mg/m2 on Day 1) with or without 5-fluorouracil (500 mg/m2 on Days 1–3) every 4 weeks. Tumor response was assessed every two cycles.
During follow-up (median 9.5 months), we recorded patient (n = 138) and disease characteristics including median age (53 years), Child-Pugh class A/B (n = 103/35, respectively), portal vein thrombosis (n = 115), and death (n = 121). In total, 561 cycles of HAIC were administered (median four cycles, range 1–14). Ninety-one patients received cisplatin plus 5-fluorouracil, while 47 received only cisplatin. The median progression-free survival (PFS) and overall survival (OS) were 6.0 and 9.5 months, respectively, while the overall disease control rate was 62.3% (3 complete responses, 29 partial responses and 54 stable diseases). Patients treated with cisplatin plus 5-fluorouracil had longer median PFS (7.0 vs. 4.6 months in those given cisplatin only; p = 0.004) and OS (12.0 vs. 7.5 months in those given cisplatin only; p = 0.001). Adverse reactions were tolerable and successfully managed with conservative treatment.
Repetitive HAIC seems well-tolerated and effective in treating advanced HCC, with more therapeutic benefit when treated with cisplatin plus 5-fluorouracil. Future randomized comparative studies are warranted for its efficacy.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Ando E, Tanaka M, Yamashita F et al (2002) Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 95:588–595
Bedenne L, Milan C, Pariente A et al (2005) Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol 23:4338–4346
Bruix J, Burroughs A, Llovet JM (2003) Hepatocellular carcinoma. Lancet 362:1907–1917
Chan SL, Mo FK, Johnson PJ et al (2009) New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol 27:446–452
Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34
Frei E, Steele G, Come S et al (1978) A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2′-deoxyuridine and 5-fluorouracil. Cancer Res 38:3784–3792
Ganeshan A, Upponi S, Hon LQ et al (2008) Hepatic arterial infusion of chemotherapy: the role of diagnostic and interventional radiology. Ann Oncol 19:847–851
Gwyther SG, Christian MC, van Oosterom AT et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216
Han KH, Park JY (2008) Chemotherapy for advanced hepatocellular carcinoma. J Gastroenterol Hepatol 23:682–684
Ikeda M, Okusaka T, Ueno H et al (2007) Hepatic arterial infusion chemotherapy with epirubicin in patients with advanced hepatocellular carcinoma and portal vein tumor thrombosis. Oncology 72:188–193
Ishikawa T, Imai M, Kamimura H et al (2007) Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a pilot study. World J Gastroenterol 13:5465–5470
Itamoto T, Nakahara H, Tashiro H et al (2002) Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein. J Surg Oncol 80:143–148
Johnston PG, Geoffrey F, Drake J et al (1996) The cellular interaction of 5-fluorouracil and cisplatin in a human colon carcinoma cell line. Eur J Cancer 32A:2148–2154
Kobayashi K, Tsuji A, Morita S et al (2006) A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinoma. BMC Cancer 6:121
Kurihara M, Shirasaka T, Matsukawa M et al (1999) Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves. Clin Cancer Res 5:2620–2628
Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390
Nakano T, Ohmori S, Deguchi M et al (2003) Low-dose chemotherapy of cisplatin and 5-fluorouracil or doxorubicin via implanted fusion port for unresectable hepatocellular carcinoma. Anticancer Res 23:1719–1722
Park JW (2004) Practice guideline for diagnosis and treatment of hepatocellular carcinoma. Korean J Hepatol 10:88–98
Park JY, Ahn SH, Yoon YJ et al (2007) Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer 110:129–137
Pisani P, Ferlay J, Bray F et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108
Reddy KR, Rudolph L, Marrero JA et al (2008) Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134:1752–1763
Riaz A, Ryu RK, Kulik LM et al (2009) Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol 27:5734–5742
Saji S, Sugiyama Y, Matsuo A et al (2004) Expression of p53 protein as a predictor of the response to 5-fluorouracil and cisplatin chemotherapy in human gastrointestinal cancer cell lines evaluated with apoptosis by use of thin layer collagen gel. Int J Oncol 24:807–813
Sherman M, Bruix J (2005) Management of hepatocellular carcinoma. Hepatology 42:1208–1236
Tse AN, Wu N, Patel D et al (2009) A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies. Cancer Chemother Pharmacol 64:935–944
Vora SR, Zheng H, Stadler ZK et al (2009) Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma. Oncologist 14:717–725
Woo HY, Bae SH, Park JY et al (2010) A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 65:373–382
Yamasaki T, Kimura T, Kurokawa F et al (2005) Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy. J Gastroenterol 40:70–78
Yoshikawa M, Ono N, Yodono H et al (2008) Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol Res 38:474–483
Zhu AX, Clark JW (2009) Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy. Oncologist 14:67–69
Zhu AX, Yen Y, Goff LW et al (2009) NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw 7:350–391
This study was supported by the Liver Cirrhosis Clinical Research Center, in part by a grant from the Brain Korea 21 Project for Medical Science, and also by a grant from the Ministry for Health, Welfare and Family Affairs, Republic of Korea (no. A050021).
Conflict of interest statement
There is no conflict of interest to report regarding this article.
About this article
Cite this article
Kim, B.K., Park, J.Y., Choi, H.J. et al. Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 137, 659–667 (2011). https://doi.org/10.1007/s00432-010-0917-5
- Hepatocellular carcinoma
- Hepatic arterial infusion chemotherapy